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Background:  Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous disease with poorly characterized phenotypes. 
Metabolomic profiling (MP) is a novel technique with the potential to distinguish high risk subtypes of HFpEF.
methods:  Targeted mass-spectrometry based MP of 69 metabolites was performed on plasma from 294 HFpEF cases from the CATHGEN 
biorepository. HFpEF was defined as an ejection fraction ≥ 50% and NYHA class II-IV within the previous 2 weeks. Principal components 
analysis (PCA) was used for multidimensional data reduction. Multivariate time-to-event analyses examined associations between factor 
levels and clinical outcomes.
results:  8 of 14 PCA-derived factors were associated with mortality. Factor 3 (short-chain dicarboxylacylcarnitines: hazard ratio [HR] 1.35 
[95% CI, 1.17-1.54], P<0.0001), factor 1 (medium-chain acylcarnitines: HR 1.28 [CI 1.08 - 1.51], P=0.005) and factor 7 (medium-chain 
acylcarnitines, HR 1.28 [1.08 - 1.51], P=0.004) were associated with increased risk of adverse events. Factor 14 (C22: HR 0.72 [0.56 
- 0.92], P=0.008), factor 8 (urea cycle amino acid: HR 0.72 [0.53 - 0.97], P=0.031) and factor 13 (non-esterified fatty acid: HR 0.77 [0.63 - 
0.94], P=0.009) were associated with a decreased risk of adverse events (Table).
conclusion:  Metabolites reporting on fatty acid oxidation and urea cycle energetic pathways independently predict adverse outcomes in 
patients with HFpEF highlighting potential biomarkers and high risk HFpEF subtypes.
